In general, these findings unveil TMPRSS2 as a bond connecting prostate cancer and COVID-19, paving the way for repurposing conventional drugs that have few on-target side effects for treating COVID-19 based on androgen suppression and TMPRSS2 protease inhibition. Here, TMPRSS2 is linked to COVID-19.